EPIX - ESSA Pharma - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

42.57M

Cash

152.5M

Avg Qtr Burn

-5.869M

Short % of Float

0.13%

Insider Ownership

5.83%

Institutional Own.

74.74%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Masofaniten (EPI-7386) (antiandrogen) combo w/ enzalutamide Details Prostate cancer, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EPI-7386 (antiandrogen) Monotherapy Details Castration-resistant prostate cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EPI-7386 (antiandrogen) comb w/ apalutamide and abiraterone acetate Details Cancer, Prostate cancer	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.